Result of General Meeting/PDMR Dealings
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your OBD notes
UNLESS OTHERWISE INDICATED, CAPITALISED TERMS IN THIS ANNOUNCEMENT HAVE THE MEANINGS GIVEN TO THEM IN THE DEFINITIONS SECTION OF THE CIRCULAR TO SHAREHOLDERS OF THE COMPANY DATED 22 OCTOBER 2025.
Oxford BioDynamics PLC
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
Result of General Meeting
Director/PDMR Dealings
7 November 2025 - Oxford BioDynamics PLC (AIM: OBD), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform announces that the resolutions proposed at the General Meeting of the Company, held earlier today, were duly passed.
Further to the passing of the resolutions at the General Meeting, applications have been made for 2,333,333,326 new ordinary shares of £0.001 each in the capital of the Company ("Ordinary Shares"), to be issued pursuant to the fundraising announced on 22 October 2025 (the "Fundraising"), to be admitted to trading on AIM, comprising: (i) 208,333,332 Placing Shares (the "VCT/EIS Placing Shares"); and (ii) 2,093,333,329 Placing Shares (the "General Placing Shares") and 31,666,665 Subscription Shares.
It is expected that admission of the VCT/EIS Placing Shares ("VCT/EIS Admission") will take place, and trading in the VCT/EIS Placing Shares will commence at 8.00 a.m. on 10 November 2025 and that admission of the General Placing Shares and the Subscription Shares ("General Admission") will take place, and trading in the General Placing Shares and the Subscription Shares will commence at 8.00 a.m. on 11 November 2025.
Following VCT/EIS Admission, the Company's issued ordinary share capital and total voting rights will consist of 2,165,910,973 Ordinary Shares. Following General Admission, the Company's issued ordinary share capital and total voting rights will consist of 4,290,910,967 Ordinary Shares. These figures should be used by shareholders as the denominator for the calculation by which they determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
The total new Ordinary Shares subscribed for pursuant to the Fundraising by the Directors and PDMRs who are participating in the Fundraising, are set out below:
| Director/PDMR | Existing beneficial shareholding | Fundraising Shares | Beneficial shareholding following the Fundraising | Shareholding as a percentage of the Enlarged Share Capital |
|---|---|---|---|---|
| Alexandre Akoulitchev | 7,562,296 | 6,666,666 | 14,228,962 | 0.33% |
| Stephan Diggle 1 | 251,876,178 | 366,666,666 | 618,542,844 | 14.4% |
| Thomas Guiel | 1,288,146 | 5,000,000 | 6,288,146 | 0.15% |
| Peter Presland | 3,398,553 | 3,333,333 | 6,731,886 | 0.16% |
| Iain Ross | 10,000,000 | 13,333,333 | 23,333,333 | 0.54% |
| Paul Stockdale | 3,077,919 | 3,333,333 | 6,411,252 | 0.15% |
1 Stephen Diggle's beneficial shareholding is held through the Vulpes Life Sciences Fund and Vulpes Testudo Fund, which are controlled by him.
Capitalised terms used but not otherwise defined in this announcement have the meanings set out in the circular published on 22 October 2025.
Director/PDMR Dealings
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Alexandre Akoulitchev | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Chief Scientific Officer, Director | ||||
| b) | Initial notification /Amendment | Initial | ||||
| a) | Name | Oxford BioDynamics Plc | ||||
| b) | LEI | 2138005Y1TK258O5U928 | ||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1p par value each ISIN: GB00BD5H8572 | ||||
| b) | Nature of the transaction | Purchase | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price | N/A | ||||
| e) | Date of the transaction | 7 November 2025 | ||||
| f) | Place of the transaction | Off market | ||||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Vulpes Investment Management (a PCA of Stephen Diggle) through Vulpes Testudo Fund | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Person closely associated with Non-Executive Director | ||||
| b) | Initial notification /Amendment | Initial | ||||
| a) | Name | Oxford BioDynamics Plc | ||||
| b) | LEI | 2138005Y1TK258O5U928 | ||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1p par value each ISIN: GB00BD5H8572 | ||||
| b) | Nature of the transaction | Purchase | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price | N/A | ||||
| e) | Date of the transaction | 7 November 2025 | ||||
| f) | Place of the transaction | Off market | ||||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Thomas Guiel | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Chief Operating Officer, PDMR | ||||
| b) | Initial notification /Amendment | Initial | ||||
| a) | Name | Oxford BioDynamics Plc | ||||
| b) | LEI | 2138005Y1TK258O5U928 | ||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1p par value each ISIN: GB00BD5H8572 | ||||
| b) | Nature of the transaction | Purchase | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price | N/A | ||||
| e) | Date of the transaction | 7 November 2025 | ||||
| f) | Place of the transaction | Off market | ||||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Peter Presland | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Non-Executive Director | ||||
| b) | Initial notification /Amendment | Initial | ||||
| a) | Name | Oxford BioDynamics Plc | ||||
| b) | LEI | 2138005Y1TK258O5U928 | ||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1p par value each ISIN: GB00BD5H8572 | ||||
| b) | Nature of the transaction | Purchase | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price | N/A | ||||
| e) | Date of the transaction | 7 November 2025 | ||||
| f) | Place of the transaction | Off market | ||||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Iain Ross | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Chairman, Director | ||||
| b) | Initial notification /Amendment | Initial | ||||
| a) | Name | Oxford BioDynamics Plc | ||||
| b) | LEI | 2138005Y1TK258O5U928 | ||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1p par value each ISIN: GB00BD5H8572 | ||||
| b) | Nature of the transaction | Purchase | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price | N/A | ||||
| e) | Date of the transaction | 7 November 2025 | ||||
| f) | Place of the transaction | Off market | ||||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Paul Stockdale | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Chief Financial Officer, Director | ||||
| b) | Initial notification /Amendment | Initial | ||||
| a) | Name | Oxford BioDynamics Plc | ||||
| b) | LEI | 2138005Y1TK258O5U928 | ||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 0.1p par value each ISIN: GB00BD5H8572 | ||||
| b) | Nature of the transaction | Purchase | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price | N/A | ||||
| e) | Date of the transaction | 7 November 2025 | ||||
| f) | Place of the transaction | Off market |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.